NCT02155335View on ClinicalTrials.gov

Preference for a Prefilled Syringe or Smartject™ Device for Delivering Golimumab in Participants Suffering From Moderate-to-severe Ulcerative Colitis (MK-8259-027)

PHASE4CompletedINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

July 1, 2014

Primary Completion Date

October 5, 2015

Study Completion Date

October 5, 2015

Conditions

Ulcerative Colitis

Interventions

DRUG

Prefilled Syringe delivery of Golimumab

Golimumab 50 mg solution for subcutaneous injection using prefilled syringe

DRUG

Smartject Device delivery of Golimumab

Golimumab 50 mg solution for subcutaneous injection using Smartject Device.

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02155335 - Preference for a Prefilled Syringe or Smartject™ Device for Delivering Golimumab in Participants Suffering From Moderate-to-severe Ulcerative Colitis (MK-8259-027) | Biotech Hunter | Biotech Hunter